Apogee Therapeutics, Inc. (NASDAQ:APGE) Position Trimmed by Point72 Asset Management L.P.

Point72 Asset Management L.P. lessened its position in Apogee Therapeutics, Inc. (NASDAQ:APGE) by 44.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 269,232 shares of the company’s stock after selling 217,968 shares during the period. Point72 Asset Management L.P. owned approximately 0.46% of Apogee Therapeutics worth $10,594,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Braidwell LP raised its holdings in shares of Apogee Therapeutics by 38.7% in the 4th quarter. Braidwell LP now owns 681,101 shares of the company’s stock worth $19,030,000 after purchasing an additional 189,988 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Apogee Therapeutics by 60.7% in the 1st quarter. Vanguard Group Inc. now owns 1,868,666 shares of the company’s stock valued at $124,173,000 after purchasing an additional 705,795 shares during the period. Jennison Associates LLC increased its stake in Apogee Therapeutics by 192.0% during the first quarter. Jennison Associates LLC now owns 302,892 shares of the company’s stock valued at $20,127,000 after acquiring an additional 199,148 shares during the period. Blackstone Inc. lifted its position in shares of Apogee Therapeutics by 17.6% during the 4th quarter. Blackstone Inc. now owns 351,810 shares of the company’s stock worth $9,830,000 after buying an additional 52,688 shares during the period. Finally, ProShare Advisors LLC acquired a new stake in shares of Apogee Therapeutics during the first quarter worth approximately $667,000. Institutional investors and hedge funds own 79.04% of the company’s stock.

Insiders Place Their Bets

In other news, insider Carl Dambkowski sold 5,995 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $37.60, for a total value of $225,412.00. Following the transaction, the insider now owns 294,793 shares of the company’s stock, valued at approximately $11,084,216.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Michael Thomas Henderson sold 40,000 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $40.62, for a total value of $1,624,800.00. Following the completion of the sale, the chief executive officer now directly owns 1,434,487 shares of the company’s stock, valued at approximately $58,268,861.94. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Carl Dambkowski sold 5,995 shares of Apogee Therapeutics stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $37.60, for a total transaction of $225,412.00. Following the transaction, the insider now directly owns 294,793 shares in the company, valued at approximately $11,084,216.80. The disclosure for this sale can be found here. In the last three months, insiders sold 120,995 shares of company stock valued at $5,218,774. 36.10% of the stock is currently owned by insiders.

Apogee Therapeutics Trading Up 1.3 %

Shares of APGE stock opened at $58.74 on Tuesday. The firm has a market capitalization of $3.43 billion, a price-to-earnings ratio of -11.19 and a beta of 2.74. The firm’s 50 day moving average is $49.11 and its 200-day moving average is $49.52. Apogee Therapeutics, Inc. has a 1 year low of $14.19 and a 1 year high of $72.29.

Apogee Therapeutics (NASDAQ:APGE) last released its earnings results on Monday, August 12th. The company reported ($0.60) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.60). On average, equities research analysts forecast that Apogee Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.